Fig. 2.

ULK1 inhibition induces selective apoptosis in FLT3-ITD AML patient-derived cells. a Cell lysates were subjected to western blotting for ULK1 expression before and after treatment of FLT3-ITD mutated (FLT3-ITD AML #0102) and FLT3-WT AML (FLT3-WT AML #0211) patients cells with the ULK1 inhibitor (MRT 68921; 2.5 μM). α-Tubulin was used as a loading control. b, c Primary leukemic blasts obtained from FLT3-ITD mutated and FLT3-WT AML patients and normal CD34+ cells obtained from healthy donors were incubated with ULK1 inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM) for 48 h. The fraction of apoptotic cells in FLT3-ITD AML, FLT3-WT AML patient cells and normal CD34+ cells treated with the ULK1 inhibitors was analyzed by flow cytometry based on Annexin-V/PI exclusion. NS, not significant